Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $170
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $150 to $170.
FDA Website Shows Dec. 22-Dated update On Antigen Tests For Omicron: ‘The FDA continues to monitor and evaluate the impact of genetic variants on antigen tests…’
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests?utm_medium=email&utm_source=govdelivery#omicronvariantimpact
President Biden Tweets ‘Starting this week, the federal government will set up emergency testing sites in areas that need additional testing capacity. Before Christmas, the first several of these federal testing sites will be up and running in New York…
https://twitter.com/POTUS/status/1473402686955479041
‘Web site will be set up next month for any US household wanting to get free #coronavirus tests delivered, says @PressSec.’ -Tweet
Web site will be set up next month for any US household wanting to get free #coronavirus tests delivered, says @PressSec.
New York Attorney General Issues Post ‘Attorney General James Issues Warning to LabQ Diagnostics to Stop Misrepresenting Turnaround Times for COVID-19 Test Results’
https://ag.ny.gov/press-release/2021/attorney-general-james-issues-warning-labq-diagnostics-stop-misrepresenting
‘Senator Calls For Federal Marijuana Standard To Measure Impaired Driving’ -Marijuana Moment Report
https://www.marijuanamoment.net/senator-calls-for-federal-marijuana-standard-to-measure-impaired-driving/